oxybutynin has been researched along with Leishmaniasis in 1 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Leishmaniasis: A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lanza, JS | 1 |
| Vucen, S | 1 |
| Flynn, O | 1 |
| Donadei, A | 1 |
| Cojean, S | 1 |
| Loiseau, PM | 1 |
| Fernandes, APSM | 1 |
| Frézard, F | 1 |
| Moore, AC | 1 |
1 other study available for oxybutynin and Leishmaniasis
| Article | Year |
|---|---|
A TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization.
Topics: Adjuvants, Immunologic; Animals; Antigens, Protozoan; Cations; Female; Immunization; Injections, Sub | 2020 |